Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.

Learn more


Therefore, we use a technology based on a trivalent antibody and equipment which is currently available at nearly all hospitals.

Learn more

Meet Our Team

Lindis Blood Care was founded by Dr. Horst Lindhofer, who was the developer of the first trifunktional antibody that was approved in Europe, Canada and Russia, and Dr. Franzpeter Bracht, who has extensive experience in setting up new companies and Business Development.

Dr. Franzpeter Bracht
Dr. Franzpeter BrachtFounder / Managing Director: Strategy, Finance and Business Development
1/2018 Foundation of Lindis Blood Care GmbH including Seed Investment (Bracht Beteiligungsgesellschaft mbH)

2017 – 6/2018 COO of Celonic AG, Basel CH & Celonic Deutschland GmbH & CoKG, Heidelberg, Germany

2007 – 2017 CFO/COO of Glycotope GmbH and Affilates

  • Developing of 3 antibodies to Phase IIb and 1 Glycoprotein up to Phase III
  • Responsible for Finance, Business Development / Marketig & Sales and Operations
  • Selling of Glycotope Biotechnology GmbH (CDMO) to Celonic AG, Basel

2007/2008 NexiGen GmbH

Foundation, Financing and successful license / trade sale deal

2006 Foundation of Bracht Beteiligungsgesellschaft mbH (BBG)

2002 – 2006 CEO/CFO of Aplagen GmbH

  • Developing of anti PL Antibodies to Clinical Phase I
  • Projects partnered with Lonza AG, Basel, CH and Bayer AG, Leverkusen, Germany

1997 – 2001 Kienbaum Management Consultants GmbH
Principal & Department Head Pharma & Life Sciences

1996 – 1997 Ernst & Young AG

PhD (Dr. rer.nat.) at the Institute for Pharmacology and Toxicology at Universität Düsseldorf

Dr. Horst Lindhofer
Dr. Horst LindhoferFounder / Managing Director: Research & Development
1/2018 Foundation of Lindis Blood Care GmbH to develop a medical device

2017 Licensing Agreement signed with an international partner for the development of several antibodies

2014-2016 Acquired selected assets developed by TRION Pharma

2010 “Galenus von Pergamon” Award for Removab in the category Specialist Care

2010 Founder of Lindis Biotech GmbH

2009 Step Award for Trion Pharma for “Product/Technology”

2009 Approval of Removab (Catumaxomab) in Europe

2002 AIO Award of the German Cancer Association, Berlin, for great contribution to tumour-biological research and development

12.1998 Co-Founder and CEO of TRION Research GmbH

05.1998 Signing of a cooperation, distribution and licensing agreement with Fresenius

03.1998 Co-Founder and CEO of TRION Pharma GmbH

1997 Paula- and Richard-von-Hertwig Award for interdisciplinary cooperation

11.1997 Head of Clinical Co-operation Group “bispecific antibodies in tumour therapy” of the Department of Otorhinolaryngology, LMU Munich, and GSF Institute of Clinical Molecular Biology and Tumour Genetics, Munich

1994 New Investigator Award on the occasion of the 23rd ISEH Congress (International Society of Experimental Hematology), Minneapolis, USA for the development of a new manufacturing process of bispecific antibodies and first results in in vivo therapy

11.1992 – 11.1997 Research Scientist at GSF Institute for Immunology, Department of Hematology, University Hospital Munich- Großhadern; Team leader “bispecific antibodies and tumour immunotherapy”


09.1989 – 09.1992 Ph.D. Student, Max-von-Pettenkofer Institute, Ludwig-Maximilians- University (LMU), Munich

Title of Ph.D. thesis: “Examination on maturation and assembly of HIV-1 with specific antibodies”

08.1989 Diploma

1983 – 1989 Study of Biology, Ludwig-Maximilians-University (LMU), Munich

Dr. Horst Lindhofer is the founder and Chief Executive Officer of LINDIS Biotech GmbH and TRION Research GmbH and. He was also the founder and Chief Executive Officer of TRION Pharma GmbH.

He studied Biology at Ludwig-Maximilians-University (LMU), Munich (Diploma) and did his PhD at Max-von- Pettenkofer Institute, Ludwig-Maximilians-University (LMU), Munich. Title of PhD thesis: “Examination on maturation and assembly of HIV-1 with specific antibodies”.

Dr. Lindhofer worked at the Helmholtz Zentrum München (1992 – 1997) as Head of a clinical cooperation group “bispecific antibodies” together with Munich’s University Hospital. He started his academic work with the improvement of existing bispecific antibody approaches and laid the foundation for the development of the triomab® concept towards an innovative and modular platform technology.

Resulting from the encouraging results of these studies he founded TRION Pharma GmbH and TRION Research GmbH in 1998 and LINDIS Biotech GmbH in 2010. All companies are located in or near Munich.

Dr. Lindhofer is author of more than 50 publications, developer of numerous patents in the field of immunotherapy and received several international awards.

Learn about our Business Model

The Next Step in
Blood Management

CATUVAB – a MEDIVAL DEVICE to remove cancer cells from blood.

Contact Us